Respiratory paralysis during treatment of hypertension with trimethaphan camsylate.
Four cases are reported in which respiratory arrest occured coincident with the intravenous administration of large doses of trimethaphan camsylate (Arfonad) to control hypertension. The mechanism of the respiratory depression is unknown, but it may have been related to a direct effect of trimethaphan on the respiratory center or to a curare-like effect of the drug. Close monitoring of ventilatory capacity should be maintained in all patients treated with trimethaphan.
D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000150:complications; D001014:Aortic Aneurysm / Q000150:complications; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D006975:Hypertension, Portal / Q000188:drug therapy; D006977:Hypertension, Renal / Q000188:drug therapy; D007263:Infusions, Parenteral; D008297:Male; D012133:Respiratory Paralysis / Q000139:chemically induced*; D014294:Trimethaphan / Q000009:adverse effects* / Q000627:therapeutic use
D014294:Trimethaphan